Why Collegium Pharmaceutical Rose Nearly 10% on Tuesday
At times, the reason or reasons behind a stock's rise are obscure or mysterious. But that certainly wasn't the case with Collegium Pharmaceutical (NASDAQ: COLL) on Tuesday, which shot 9.8% higher thanks to a development that should dramatically raise its profile.
Collegium, a biotech that has enjoyed success with its pain relief medication Xtampza ER, is about to become a component of the S&P stock index family.
Late Monday, S&P Dow Jones Indices -- the operator of the famous suite of indexes -- announced a change in its benchmark S&P 500 index.
Source Fool.com
